Challenges of bringing a new sedative to market!
Author:
- 1 August 2018
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Anaesthesiology
- Vol. 31 (4) , 423-430
Abstract
The current review examines the success and failures of the development of new hypnotic compounds for the human market. One of the important aspects is that one of the key present agents, propofol, is considered by many anaesthesiologists as ‘the ideal’. However, all drugs have adverse or side-effects. The last 30 years since the introduction of propofol has seen many new compounds evaluated; but as at the present time, only three agents may achieve a pivotal position in the market – fospropofol (a sedative agent which may have a role in endoscopic surgery); remimazolam (a short-acting benzodiazepine) whose development is also being focused on the sedation rather than anaesthesia market; and the pregnane steroid, alfaxalone (an anaesthetic agent first introduced in 1972, but withdrawn in 1984 because of adverse allergic reactions to the solvent, Cremophor EL) now solvented in a cyclodextrin. Studies of these three agents thus far have shown that none of them has any major adverse side-effects; all have properties which warrant further clinical evaluation.Keywords
This publication has 41 references indexed in Scilit:
- Adrenocortical suppression and recovery after continuous hypnotic infusion: etomidate versus its soft analogue cyclopropyl-methoxycarbonyl metomidateCritical Care, 2013
- CarboetomidateAnesthesiology, 2010
- Methoxycarbonyl-etomidateAnesthesiology, 2009
- The pharmacokinetics and pharmacodynamics of alfaxalone in cats after single and multiple intravenous administration of Alfaxan®at clinical and supraclinical dosesJournal of Veterinary Pharmacology and Therapeutics, 2008
- CNS 7056Anesthesiology, 2007
- Pharmacokinetics and Pharmacodynamics of Propofol Microemulsion and Lipid Emulsion after an Intravenous Bolus and Variable Rate InfusionAnesthesiology, 2007
- Plasma pharmacokinetics of alfaxalone in dogs after an intravenous bolus of Alfaxan-CD RTUVeterinary Anaesthesia and Analgesia, 2006
- AQUAVAN® Injection, a Water-soluble Prodrug of Propofol, as a Bolus Injection: A Phase I Dose-escalation Comparison with DIPRIVAN® (Part 2): Pharmacodynamics and Safety: RetractedAnesthesiology, 2005
- An intravenous toxicity study of 2-hydroxypropyl-β-cyclodextrin, a useful drug solubilizer, in rats and monkeys☆International Journal of Pharmaceutics, 1990
- Intravenous anaesthesia by infusionAnaesthesia, 1975